Highlight
– In the MARIPOSA exploratory, double-blind comparison, lazertinib monotherapy produced median progression-free survival (PFS) of 18.5 months versus 16.6 months for osimertinib (HR 0.98; p = 0.86), indicating comparable efficacy.
– Objective response rates (ORR) and median duration of response (DoR) were similar between arms (ORR 83% vs 85%; DoR 16.6 vs 16.8 months).
– At interim analysis, median overall survival (OS) was not reached in either arm (HR 1.00). Safety profiles were broadly comparable; lazertinib had lower rates of QT interval prolongation than osimertinib.